Iron deficiency and cardiovascular disease

Nature Reviews Cardiology

Volumn 12, Issue 11, 2015, Pages 659-669

  Von Haehling, Stephan ^a   Jankowska, Ewa A ^b   Van Veldhuisen, Dirk J ^c   Ponikowski, Piotr ^b   Anker, Stefan D ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; IRON; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; CARDIOVASCULAR DISEASE; HEART FAILURE; HEART SURGERY; HEART TRANSPLANTATION; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON THERAPY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANEMIA, IRON-DEFICIENCY; COMPLICATION; METABOLISM; RISK FACTOR;

ANEMIA, IRON-DEFICIENCY; CARDIOVASCULAR DISEASES; HUMANS; IRON; RISK FACTORS;

EID: 84945487486     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.109     Document Type: Review

References (93)

1. DeMaeyer, E., & Adiels-Tegman, M. The prevalence of anaemia in the world. World Health Stat. Q. 38, 302-316 (1985
2. Stoltzfus, R. Defining iron-deficiency anemia in public health terms: a time for reflection. J. Nutr. 131, 565S-567S (2001
3. Lundqvist, H., & Sjöberg, F. Food interaction of oral uptake of iron /a clinical trial using. 59Fe. Arzneimittelforschung. 57, 401-416 (2007
4. Andrews, N. C., & Schmidt, P. J. Iron homeostasis. Annu. Rev. Physiol. 69, 69-85 (2007
5. Andrews, N. C. Disorders of iron metabolism. N. Engl. J. Med. 341, 1986-1995 (1999
6. Zimmermann, M. B. The influence of iron status on iodine utilization and thyroid function. Annu. Rev. Nutr. 26, 367-389 (2006
7. Moos, T. Brain iron homeostasis. Dan. Med. Bull. 49, 279-301 (2002
8. Christian, P., et al. Prenatal micronutrient supplementation and intellectual and motor function in early school-Aged children in Nepal. JAMA. 304, 2716-2723 (2010
9. Fairweather-Tait, S. J., Wawer, A. A., Gillings, R., Jennings, A., & Myint, P. K. Iron status in the elderly. Mech. Ageing Dev. 136-137, 22-28 (2014
10. Finch, C. A., et al. Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction. J. Clin. Invest. 58, 447-453 (1976
11. Beard, J. L. Iron biology in immune function, muscle metabolism and neuronal functioning. J. Nutr. 131, 568S-579S (2001
12. Silverberg, D. S., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol. 35, 1737-1744 (2000
13. van Veldhuisen, D. J., Anker, S. D., Ponikowski, P., & Macdougall, I. C. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat. Rev. Cardiol. 8, 485-493 (2011
14. Sullivan, J. L. Iron and the sex difference in heart disease risk. Lancet. 317, 1293-1294 (1981
15. Ganz, T., & Nemeth, E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G199-G203 (2006
16. Jankowska, E. A, von Haehling, S., Anker, S. D., Macdougall, I. C., & Ponikowski, P. P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur. Heart J. 34, 816-829 (2013
17. Monsen, E. R. Iron and absorption: dietary factors which impact iron bioavailability. J. Am. Diet. Assoc. 88, 786-790 (1988
18. Nemeth, E., & Ganz, T. The role of hepcidin in iron metabolism. Acta Haematol. 122, 78-86 (2009
19. Schaefer, B., Effenberger, M., & Zoller, H. Iron metabolism in transplantation. Transpl. Int. 27, 1109-1117 (2014
20. Cook, J. D. Diagnosis and management of iron deficiency anaemia. Best Pract. Res. Clin. Haematol. 18, 319-332 (2005
21. Geisser, P. Safety and efficacy of iron(III)-hydroxide polymaltose complex /a review of over. 25 years experience. Arzneimittelforschung. 57, 439-452 (2007
22. von Haehling, S., & Anker, S. D. in Iron Deficiency and Anaemia in Heart Failure 2nd edn (Anker S. D., & von Haehling, S.) 68-83 (UNI-MED, 2012
23. Auerbach, M., & Ballard, H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am. Soc. Hematol. Educ. Program. 2010, 338-347 (2010
24. Lauffer, R. B. Iron depletion and coronary disease. Am. Heart J. 119, 1448-1449 (1990
25. Salonen, J. T., et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 86, 803-811 (1992
26. de Valk, B., & Marx, J. J. Iron, atherosclerosis, and ischemic heart disease. Arch. Intern. Med. 159, 1542-1548 (1999
27. Ma, J., & Stampfer, M. J. Body iron stores and coronary heart disease. Clin. Chem. 48, 601-603 (2002
28. Danesh, J., & Appleby, P. Coronary heart disease and iron status: meta-Analyses of prospective studies. Circulation. 99, 852-854 (1999
29. Wood, R. J. The iron-heart disease connection: is it dead or just hiding?. Ageing Res. Rev. 3, 355-367 (2004
30. Das De, S., Krishna, S., & Jethwa, A. Iron status and its association with coronary heart disease: systematic review and meta-Analysis of prospective studies. Atherosclerosis. 238, 296-303 (2015
31. Kang, P., Liu, T., Tian, C., Zhou, Y., & Jia, C. Association of total iron binding capacity with coronary artery disease. Clin. Chim. Acta. 413, 1424-1429 (2012
32. Ascherio, A., Rimm, E. B., Giovannucci, E., Willett, W. C., & Stampfer, M. J. Blood donations and risk of coronary heart disease in men. Circulation. 103, 52-57 (2001
33. Grammer, T. B., et al. Hemoglobin, iron metabolism and angiographic coronary artery disease (The Ludwigshafen Risk and Cardiovascular Health Study). Atherosclerosis. 236, 292-300 (2014
34. Ponikowska, B., et al. Iron status and survival in diabetic patients with coronary artery disease. Diabetes Care. 36, 4147-4156 (2013
35. Jankowska, E. A., et al. Bone marrow iron depletion is common in patients with coronary artery disease. Int. J. Cardiol. 182, 517-522 (2015
36. Anand, I. S., et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 112, 1121-1127 (2005
37. Felker, G. M., Shaw, L. K., Stough, W. G., & OConnor, C. M. Anemia in patients with heart failure and preserved systolic function. Am. Heart J. 151, 457-462 (2006
38. Go, A. S., et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation. 113, 2713-2723 (2006
39. Komajda, M., et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur. Heart J. 27, 1440-1446 (2006
40. OMeara, E., et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 113, 986-994 (2006
41. von Haehling, S., et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. Eur. J. Heart Fail. 13, 656-663 (2011
42. Anker, S. D., et al. Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. Eur. Heart J. 30, 1331-1339 (2009
43. von Haehling, S., Anker, M. S., Jankowska, E. A., Ponikowski, P., & Anker, S. D. Anemia in chronic heart failure: can we treat?. What to treat?. Heart Fail. Rev. 17, 203-210 (2012
44. Anand, I. S. Anemia and chronic heart failure implications and treatment options. J. Am. Coll. Cardiol. 52, 501-511 (2008
45. Westenbrink, B. D., et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur. Heart J. 28, 166-171 (2007
46. Weiss, G., & Goodnough, L. T. Anemia of chronic disease. N. Engl. J. Med. 352, 1011-1023 (2005
47. Ebner, N., & von Haehling, S. Iron deficiency in heart failure: a practical guide. Nutrients. 5, 3730-3739 (2013
48. Ezekowitz, J. A., McAlister, F. A., & Armstrong, P. W. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of. 12 065 patients with new-onset heart failure. Circulation. 107, 223-225 (2003
49. Nanas, J. N., et al. Etiology of anemia in patients with advanced heart failure. J. Am. Coll. Cardiol. 48, 2485-2489 (2006
50. Jankowska, E. A., et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur. Heart J. 31, 1872-1880 (2010
51. Parikh, A., Natarajan, S., Lipsitz, S. R., & Katz, S. D. Iron deficiency in community-dwelling US adults with self-reported heart failure in the National Health and Nutrition Examination Survey III: prevalence and associations with anemia and inflammation. Circ. Heart Fail. 4, 599-606 (2011
52. Silverberg, D. S., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol. 37, 1775-1780 (2001
53. Silverberg, D. S., et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol. Dial. Transplant. 18, 141-146 (2003
54. Mancini, D. M., et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 107, 294-299 (2003
55. Palazzuoli, A., et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am. Heart J. 152, 1096.e9-1096.e15 (2006
56. Ponikowski, P., et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 49, 753-762 (2007
57. van Veldhuisen, D. J., et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur. Heart J. 28, 2208-2216 (2007
58. Ghali, J. K., et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 117, 526-535 (2008
59. Swedberg, K., et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N. Engl. J. Med. 368, 1210-1219 (2013
60. Bolger, A. P., et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J. Am. Coll. Cardiol. 48, 1225-1227 (2006
61. Toblli, J. E., Lombraña, A., Duarte, P., & Di Gennaro, F. Intravenous iron reduces NT pro brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J. Am. Coll. Cardiol. 50, 1657-1665 (2007
62. Okonko, D. O., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J. Am. Coll. Cardiol. 51, 103-112 (2008
63. Anker, S. D., et al. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur. J. Heart Fail. 11, 1084-1091 (2009
64. Anker, S. D., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 361, 2436-2448 (2009
65. McMurray, J. J., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14, 803-869 (2012
66. Krum, H., et al. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Med. J. Aust. 194, 405-409 (2011
67. Yancy, C. W., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62, e147-e239 (2013
68. Ponikowski, P., et al. Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Failure. 1, 52-58 (2014
69. Clark, A. L., & Pellicori, P. Clinical trials update from the European Society of Cardiology meeting. 2014: PARADIGM-HF, CONFIRM-HF, SIGNIFY, atrial fibrillation, beta-blockers and heart failure, and vagal stimulation in heart failure. ESC Heart Failure. 1, 82-86 (2014
70. Ponikowski, P., et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur. Heart J. 36, 657-668 (2015
71. US National Library of Medicine ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01394562 (2015
72. von Haehling, S. Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. Int. J. Cardiol. 144, 206-211 (2010
73. Soon, E., et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax. 66, 326-332 (2011
74. Ruiter, G., et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 37, 1386-1391 (2011
75. van Empel, V. P., Lee, J., Williams, T. J., & Kaye, D. M. Iron deficiency in patients with idiopathic pulmonary arterial hypertension. Heart Lung Circ. 23, 287-292 (2014
76. Rhodes, C. J., et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J. Am. Coll. Cardiol. 58, 300-309 (2011
77. Viethen, T., et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int. J. Cardiol. 175, 233-239 (2014
78. Gleissner, C. A., et al. Reduced hemoglobin after heart transplantation is no independent risk factor for survival but is associated closely with impaired renal function. Transplantation. 77, 710-717 (2004
79. Przybylowski, P., Malyszko, J., & Malyszko, J. Anemia is a predictor of outcome in heart transplant recipients. Transplant. Proc. 41, 3228-3231 (2009
80. Taegtmeyer, A. B., et al. The effects of pre- and post-transplant anemia on. 1 year survival after cardiac transplantation. J. Heart Lung Transplant. 27, 394-399 (2008
81. Przybylowski, P., et al. Prevalence of iron deficiency in heart and kidney allograft recipients. Transplant. Proc. 43, 3885-3887 (2011
82. Schaefer, B., Effenberger, M., & Zoller, H. Iron metabolism in transplantation. Transpl. Int. 27, 1109-1117 (2014
83. Menasché, P., Grousset, C., Mouas, C., & Piwnica, A. A promising approach for improving the recovery of heart transplants. Prevention of free radical injury through iron chelation by deferoxamine. J. Thorac. Cardiovasc. Surg. 100, 13-21 (1990
84. Macedo, M. F., et al. Transferrin is required for early T cell differentiation. Immunology. 112, 543-549 (2004
85. Zheng, Y., et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J. Immunol 178 2163-2170 2007
86. Brekelmans, P., Van Soest, P., Leenen, P. J., & Van Ewijk, W. Inhibition of proliferation and differentiation during early T cell development by anti-transferrin receptor antibody. Eur. J. Immunol. 24, 2896-2902 (1994
87. David, O., Sinha, R., Robinson, K., & Cardone, D. The prevalence of anaemia, hypochromia and microcytosis in preoperative cardiac surgical patients. Anaesth. Intensive Care. 41, 316-321 (2013
88. Hung, M., et al. A prospective observational cohort study to identify the causes of anaemia and association with outcome in cardiac surgical patients. Heart 101 107-112 2015
89. Piednoir, P., et al. Preoperative iron deficiency increases transfusion requirements and fatigue in cardiac surgery patients: a prospective observational study. Eur. J. Anaesthesiol. 28, 796-801 (2011
90. Madi-Jebara, S. N., et al. Postoperative intravenous iron used alone or in combination with low-dose erythropoietin is not effective for correction of anemia after cardiac surgery. J. Cardiothorac. Vasc. Anesth. 18, 59-63 (2004
91. Garrido-Martín, P., et al. The effect of intravenous and oral iron administration on perioperative anaemia and transfusion requirements in patients undergoing elective cardiac surgery: a randomized clinical trial. Interact. Cardiovasc. Thorac. Surg. 15, 1013-1018 (2012
92. Wish, J. B. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin. J. Am. Soc. Nephrol. 1 (Suppl. 1), S4-S8 (2006
93. Usmanov, R. I., Zueva, E. B., Silverberg, D. S., & Shaked, M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J. Nephrol. 21, 236-242 (2008